Trial Profile
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Anal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 11 Apr 2024 Planned End Date changed from 31 Aug 2024 to 31 Dec 2025.
- 11 Apr 2024 Planned primary completion date changed from 31 Aug 2024 to 31 Dec 2025.
- 18 Mar 2023 Planned End Date changed from 30 Dec 2023 to 31 Aug 2024.